

(12) UK Patent Application (19) GB (11) 2 177 096 A

(43) Date of printing by UK Office 14 Jan 1987

(21) Application No 8608827

(22) Date of filing 3 Sep 1985

(30) Priority data

(31) 8422238

(32) 2 Sep 1984

(33) GB

(86) International application data
PCT/GB85/00392 En 3 Sep 1985

(87) International publication data
WO86/01533 En 13 Mar 1986

(71) Applicant
Celltech Limited

(Incorporated in United Kingdom),

244—250 Bath Road, Slough, Berkshire SL1 4DY

(72) Inventors
Michael Samuel Neuberger,
Terence Howard Rabbitts

(51) INT CL⁴ (as given by ISA)

C12N 15/00 A61K 39/395 C07K 3/18 15/00 C12N 5/00
C12P 21/00 G01N 33/563

(52) Domestic classification (Edition I)

C3H 431 642 656 675 690 B7M

C6Y 404 501 503

U1S 2419 C3H

(56) Documents cited by ISA

EP A 0150126

EP A 0090898

EP A 0125023

EP A 0068763

EP A 0120694

WO A 83/03971

EP A 0105521

WO A 84/00382

Chemical Abstracts, volume 95, no. 4, 27 July 1981,
page 363, abstract 30711m

Nature, 314 no. 6010, April 1985, pages 452-454

Nature, 314, no. 6008, 21 March 1985, pages 268-270

Nature 312, no. 5995, December 1984, pages 643-646

Nature 312, no. 5995, December 1984, pages 604-608

(58) Field of search by ISA


IPC⁴ C12N; C12P

(74) Agent and/or Address for Service

Carpmaels & Ransford, 43 Bloomsbury Square, London
WC1A 2RA.

(54) Production of chimeric antibodies

(57) A process for the production of a chimeric antibody, comprising: a) preparing a replicable expression vector including a suitable promoter operably linked to a DNA sequence comprising a first path which encodes at least the variable region of the heavy or light chain of an Ig molecule and a second part which encodes at least part of a second protein; b) if necessary, preparing a replicable expression vector including a suitable promoter operably linked to a DNA sequence which encodes at least the variable region of a complementary light or heavy chain respectively of an Ig molecule; c) transforming an immortalised mammalian cell line with the or both prepared vectors; and d) culturing said transformed cell line to produce the chimeric antibody; chimeric antibodies produced by this process; and plasmids and transformed cell lines used in the process.



GB 2 177 096 A